Biogen Eyes Massive Layoffs in Wake of Disappointing Aduhelm Rollout

Massive layoffs could be headed to Biogen due to the disappointing rollout of its Alzheimer's drug Aduhelm that generated only a few million dollars in revenue over the past two quarters. The company could lay off as many as 1,000 employees as it continues to deal with the controversial treatment.